TITLE

FDA Drug Approvals

PUB. DATE
January 2001
SOURCE
Formulary;Jan2001, Vol. 36 Issue 1, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduces drugs approved by the United States Food and Drug Administration (FDA). Use of Azelastine HCL in treating symptoms of vasomotor rhinitis; Application of Enoxaparin sodium for prophylaxis of deep vein thrombosis; Efficacy of Neurontin, an antiepileptic drug.
ACCESSION #
3982776

 

Related Articles

  • FDA dispenses advice on patient testimonials. Dickinson, James G. // Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p14 

    The article reports on the advice given by the U.S. Food and Drug Administration (FDA) to drug marketers on how to incorporate patient testimonials and case studies into their advertising and promotion.

  • FDA cites Sanofi-Synthelabo on Plavix promo.  // Medical Marketing & Media;Jul2001, Vol. 36 Issue 7, p32 

    Focuses on the comments of the U.S. Food and Drug Administration over the use of visual sales aid for the marketing of anti-platelet drug Plavix by Sanofi-Synthelabo company.

  • FDA Actions.  // Clinical Cardiology Alert;Mar2010 Supplement 2, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the marketing of diabetes drug, liraglutide under the trade name of Victoza, in March 2010.

  • FDA Urging Docs to Report Bad Ads.  // BioWorld Today;5/17/2010, Vol. 21 Issue 94, p3 

    This article reports on the launch of a program by the U.S. Food and Drug Administration (FDA) to encourage prescribers to report misleading drug promotional activities to the agency.

  • AIDS wasting agent approved.  // Drug Topics;9/2/96, Vol. 140 Issue 17, p7 

    Presents information on injectionable drugs given marketing approval by the Food and Drug Administration. Serostim manufactured by Serono Laboratories as treatment for AIDS wasting; Fertinex for use in combination with hCG as treatment for infertility.

  • Rx marketers 'test' FDA guides on print DTC ads. Wilke, Michael // Advertising Age;4/6/1998, Vol. 69 Issue 14, p18 

    Reports that pharmaceutical marketers continue to experiment with controversial advertising which carry only the side effects of products. Reasons for this; Role the United States Food & Drug Administration has in the advertising methods; How certain groups are pushing for more...

  • More NDAs filed in '97, fewer refused.  // Medical Marketing & Media;Feb98, Vol. 33 Issue 2, p28 

    Reports on the total number of applications submitted to the US Food and Drug Administration (FDA) for the marketing of new drugs and biologics in 1998. Implementation of the Prescription Drug User Fee Acrt in 1997.

  • Drug user fee rates jump 72 percent in FY 2003.  // Medical Marketing & Media;Sep2002, Vol. 37 Issue 9, p38 

    Reports the rate increase for drug marketing applications submitted to the U.S. Food and Drug Administration. Reaction of the pharmaceutical industry on the increase; Percentage increase of application; Cost of applications containing clinical data.

  • 'Breakthrough' drugs may carry more risk.  // Consumer Reports on Health;Oct2006, Vol. 18 Issue 10, p1 

    The article provides information on 'me too' medicines which are modestly dissimilar from the existing ones approved by the U.S. Food and Drug Administration. The brand-new compounds constitute 25 percent called new molecular entities (NME). These drugs offer hope for improved treatments, but...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics